Literature DB >> 1395977

Short-chain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis.

A J Senagore1, J M MacKeigan, M Scheider, J S Ebrom.   

Abstract

The purpose of this study was to perform a randomized, prospective comparison of corticosteroid enemas (CS--100 mg of hydrocortisone/60 cc P.R. q.h.s.; n = 12), mesalamine enemas (5-ASA--4 g/60 cc P.R. q.h.s.; n = 19), and short-chain fatty acid enemas (SCFA--60 cc P.R. b.i.d.; n = 14) for the treatment of proctosigmoiditis. Patients presenting to the Ferguson Clinic with the diagnosis of idiopathic proctosigmoiditis were evaluated for age, sex, prior history of proctitis, duration of symptoms prior to presentation, endoscopic scoring, and mucosal biopsies. Clinical evaluation was performed at two-week intervals for six weeks, with repeat biopsies taken at six weeks. There was no significant difference with respect to age, male/female ratio, past history of proctosigmoiditis, length of colorectum involved at the time of initial presentation, symptom resolution, and endoscopic and histologic improvement among the three treatment groups. Recovery occurred in a similar proportion in each of the three groups: CS, 10/12; 5-ASA, 17/19; and SCFA, 12/14. The cost of six weeks of treatment was: CS, $71.82; 5-ASA, $347.28; and SCFA, $31.50. This study indicates that SCFA enemas are equally efficacious to CS or 5-ASA enemas for the treatment of proctosigmoiditis at a significant cost savings.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1395977     DOI: 10.1007/bf02253492

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  24 in total

Review 1.  Clinical nutrition: 6. Management of nutritional problems of patients with Crohn's disease.

Authors:  Khursheed N Jeejeebhoy
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

2.  Oxidation of short and medium chain C2-C8 fatty acids in Sprague-Dawley rat colonocytes.

Authors:  J R Jørgensen; M R Clausen; P B Mortensen
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 3.  Nutritional modulation of the inflammatory response in inflammatory bowel disease--from the molecular to the integrative to the clinical.

Authors:  Gary E Wild; Laurie Drozdowski; Carmela Tartaglia; M Tom Clandinin; Alan B R Thomson
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 4.  AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Siddharth Singh; Joseph D Feuerstein; David G Binion; William J Tremaine
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

Review 5.  AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Cynthia W Ko; Siddharth Singh; Joseph D Feuerstein; Corinna Falck-Ytter; Yngve Falck-Ytter; Raymond K Cross
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

Review 6.  Hydrogen sulphide: a bacterial toxin in ulcerative colitis?

Authors:  M C Pitcher; J H Cummings
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

Review 7.  Reevaluating the hype: four bacterial metabolites under scrutiny.

Authors:  E E Fröhlich; R Mayerhofer; P Holzer
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-03-26

8.  Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial.

Authors:  R I Breuer; K H Soergel; B A Lashner; M L Christ; S B Hanauer; A Vanagunas; J M Harig; A Keshavarzian; M Robinson; J H Sellin; D Weinberg; D E Vidican; K L Flemal; A W Rademaker
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 9.  [What is the role of nutrition in ulcerative colitis? A contribution to the current status of diet therapy in treatment of inflammatory bowel diseases].

Authors:  M Bartels; E Nagel; R Pichlmayr
Journal:  Langenbecks Arch Chir       Date:  1995

10.  Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis.

Authors:  M A Chapman; M F Grahn; M A Boyle; M Hutton; J Rogers; N S Williams
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.